Product image of Montelukast Heumann (Montelukast) supplied by GNH India

Montelukast Heumann

Active Ingredient:
Montelukast
Origin:
EU

Montelukast Heumann (Montelukast)

Montelukast, the active ingredient in Montelukast Heumann, is a leukotriene receptor antagonist presented as an oral tablet for systemic use. It is employed to manage chronic asthma, allergic rhinitis, and exercise‑induced bronchoconstriction in adult and pediatric patients as directed by a healthcare professional.

GNH India supplies Montelukast Heumann as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product meets EU quality standards and is manufactured under strict GMP conditions.

Manufacturer / TM Owner

Heumann Pharma Gmbh & Co. Generica Kg

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Montelukast acts on the leukotriene pathway to control inflammation and bronchoconstriction in several allergic respiratory conditions.

  • Asthma: reduces frequency of symptoms and improves lung function in persistent asthma.
  • Allergic rhinitis: alleviates nasal congestion, sneezing and itching caused by seasonal or perennial allergens.
  • Exercise‑induced bronchoconstriction: prevents airway narrowing triggered by physical activity.

How It Works

  • Montelukast selectively blocks the cysteinyl leukotriene receptor type 1 (CysLT1) on airway smooth‑muscle cells, mast cells and eosinophils. By preventing leukotriene D4 and related mediators from binding, it inhibits bronchoconstriction, mucus secretion and inflammatory cell recruitment, thereby reducing airway hyper‑responsiveness and allergic inflammation.

Side Effects

Montelukast may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

  • Headache: mild to moderate pain often occurring early in therapy.
  • Abdominal pain: discomfort or cramps in the stomach region.
  • Cough: transient dry cough.
  • Diarrhea: loose stools.
  • Nasopharyngitis: common cold‑like symptoms.
  • Fatigue: feeling of tiredness.

Serious or Rare Side Effects

  • Neuropsychiatric events: agitation, depression, suicidal thoughts.
  • Allergic reactions: rash, urticaria, angioedema.
  • Hepatotoxicity: elevated liver enzymes or hepatitis.
  • Stevens‑Johnson syndrome: severe skin blistering.
  • Anaphylaxis: rapid onset of systemic allergic response.

Precautions & Warnings

When prescribing Montelukast, clinicians should consider several safety and monitoring points.

  • Monitor liver function: assess transaminases in patients with hepatic disease.
  • Use caution in psychiatric history: observe for mood changes or suicidal ideation.
  • Avoid in known hypersensitivity: discontinue if rash or angioedema occurs.
  • Not for acute asthma attacks: provide rescue bronchodilator instead.
  • Adjust in renal impairment: consider dose reduction in severe renal failure.
  • Store at room temperature: keep in original container, protect from moisture and light.

Avoid Interactions

Montelukast has documented interactions that may alter its effectiveness or increase risk of adverse effects.

Major Interactions (Avoid)

  • Phenobarbital: enzyme induction reduces montelukast plasma levels.
  • Rifampin: strong CYP inducer decreases therapeutic exposure.
  • Carbamazepine: induces metabolism leading to loss of efficacy.

Moderate Interactions (Monitor Closely)

  • Ketoconazole: CYP3A4 inhibition may increase montelukast concentration.
  • Erythromycin: moderate increase in drug levels.
  • Fluconazole: may raise plasma concentrations modestly.
  • Warfarin: potential alteration of anticoagulant effect; monitor INR.

Frequently Asked Questions

Montelukast Heumann is prescribed to treat persistent asthma, allergic rhinitis and exercise‑induced bronchoconstriction. It helps control airway inflammation and reduces symptoms such as wheezing, nasal congestion, sneezing and exercise‑related shortness of breath.

Montelukast works by selectively blocking the cysteinyl leukotriene receptor type 1 (CysLT1). This prevents leukotrienes, which are inflammatory mediators, from binding to airway cells, thereby reducing bronchoconstriction, mucus production and inflammatory cell recruitment.

The appropriate dose of Montelukast Heumann is determined by the prescribing clinician based on the patient’s age, weight, indication and clinical response. Dosage instructions are provided on the prescription label and should be followed exactly as directed.

Safety data for Montelukast in pregnancy and lactation are limited. Health‑care providers weigh the potential benefits against possible risks before prescribing it to pregnant or nursing women. Patients should discuss any concerns with their physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Montelukast belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids or long‑acting beta‑agonists. It is particularly useful for patients with allergic components or those who experience exercise‑induced bronchoconstriction, but it is generally used as add‑on therapy rather than a sole rescue medication.

Montelukast Heumann should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight and excessive heat to maintain its stability and potency.

Montelukast Heumann is taken orally, usually once daily in the evening, with or without food. The tablet should be swallowed whole with a glass of water and not chewed or crushed unless otherwise instructed by a health‑care professional.

Serious risks include neuropsychiatric events such as depression, agitation or suicidal thoughts, as well as severe allergic reactions like anaphylaxis, Stevens‑Johnson syndrome and liver injury. Patients should seek immediate medical attention if they notice any of these symptoms.

Montelukast Heumann is contraindicated in individuals with known hypersensitivity to montelukast or any of the tablet’s excipients. It should not be used as a rescue medication for acute asthma attacks, and patients with uncontrolled severe hepatic disease should be evaluated carefully before use.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Montelukast

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT